Research progress on the immunomodulatory mechanism of acupuncture in tumor immune microenvironment.

Na Wang, Lu Zhao, Dou Zhang, Fanming Kong
Author Information
  1. Na Wang: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  2. Lu Zhao: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  3. Dou Zhang: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  4. Fanming Kong: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Abstract

With the constantly deeper understanding of individualized precision therapy, immunotherapy is increasingly developed and personalized. The tumor immune microenvironment (TIME) mainly consists of infiltrating immune cells, neuroendocrine cells, extracellular matrix, lymphatic vessel network, etc. It is the internal environment basis for the survival and development of tumor cells. As a characteristic treatment of traditional Chinese medicine, acupuncture has shown potentially beneficial impacts on TIME. The currently available information demonstrated that acupuncture could regulate the state of immunosuppression through a range of pathways. An effective way to understand the mechanisms of action of acupuncture was to analyze the response following treatment of the immune system. This research reviewed the mechanisms of acupuncture regulating tumor immunological status based on innate and adaptive immunity.

Keywords

References

  1. Exp Mol Med. 2018 Dec 13;50(12):1-11 [PMID: 30546008]
  2. Front Immunol. 2020 May 21;11:924 [PMID: 32508825]
  3. Brain Behav Immun. 2018 Feb;68:132-145 [PMID: 29051087]
  4. Front Immunol. 2019 Jul 03;10:1462 [PMID: 31333642]
  5. J Tradit Chin Med. 1993 Sep;13(3):174-8 [PMID: 8246585]
  6. Nat Rev Clin Oncol. 2019 Oct;16(10):601-620 [PMID: 31160735]
  7. J Integr Med. 2021 May;19(3):251-257 [PMID: 33642209]
  8. Life Sci. 2021 Jan 1;264:118699 [PMID: 33137368]
  9. Front Immunol. 2020 Aug 04;11:1731 [PMID: 32849616]
  10. Front Immunol. 2019 Jan 21;9:3176 [PMID: 30719026]
  11. Cancer Res. 2019 Sep 15;79(18):4557-4566 [PMID: 31350295]
  12. Am J Transl Res. 2021 Jul 15;13(7):8118-8125 [PMID: 34377295]
  13. Science. 2011 Mar 25;331(6024):1565-70 [PMID: 21436444]
  14. Inflammation. 2018 Jun;41(3):859-869 [PMID: 29404871]
  15. Support Care Cancer. 2017 Dec;25(12):3807-3814 [PMID: 28707168]
  16. Clin Rev Allergy Immunol. 2013 Jun;44(3):254-61 [PMID: 22661215]
  17. PLoS One. 2018 Mar 7;13(3):e0194022 [PMID: 29513755]
  18. J Integr Med. 2013 Mar;11(2):101-5 [PMID: 23762897]
  19. Annu Rev Pathol. 2020 Jan 24;15:123-147 [PMID: 31530089]
  20. Chin J Integr Med. 2016 Mar;22(3):219-24 [PMID: 26825083]
  21. Adv Exp Med Biol. 2017;1036:33-49 [PMID: 29275463]
  22. Evid Based Complement Alternat Med. 2015;2015:340126 [PMID: 26612993]
  23. Biomed Pharmacother. 2020 May;125:109898 [PMID: 32004977]
  24. Front Immunol. 2018 Dec 11;9:2909 [PMID: 30619273]
  25. Biomed Res Int. 2022 Jul 11;2022:7037497 [PMID: 35860804]
  26. JAMA Oncol. 2021 Sep 1;7(9):1399-1400 [PMID: 34323934]
  27. Biomed Pharmacother. 2021 Feb;134:111001 [PMID: 33341053]
  28. Acupunct Med. 2019 Oct;37(5):292-300 [PMID: 31192694]
  29. Evid Based Complement Alternat Med. 2007 Mar;4(1):51-7 [PMID: 17342241]
  30. Contrast Media Mol Imaging. 2022 Aug 18;2022:3444360 [PMID: 36051923]
  31. Nat Immunol. 2021 Apr;22(4):412-422 [PMID: 33603227]
  32. Evid Based Complement Alternat Med. 2011;2011:481625 [PMID: 21785626]
  33. J Inflamm Res. 2021 Dec 21;14:7191-7224 [PMID: 34992414]
  34. QJM. 2014 May;107(5):341-5 [PMID: 24106314]
  35. J Pain Res. 2020 Jan 29;13:239-250 [PMID: 32099448]
  36. Evid Based Complement Alternat Med. 2017;2017:3647080 [PMID: 28588637]
  37. Mol Neurobiol. 2015 Feb;51(1):19-31 [PMID: 24961568]
  38. Med Acupunct. 2019 Feb 1;31(1):29-36 [PMID: 30805077]
  39. Mol Cancer. 2017 Aug 15;16(1):137 [PMID: 28810877]
  40. Neural Plast. 2020 Aug 28;2020:8836173 [PMID: 32908486]
  41. Am J Chin Med. 2018;46(5):997-1019 [PMID: 30001644]
  42. Acupunct Med. 2017 Jun;35(3):224-230 [PMID: 28077367]
  43. Adv Exp Med Biol. 2017;1011:211-223 [PMID: 28875492]
  44. Front Immunol. 2018 Apr 05;9:527 [PMID: 29675018]
  45. Nature. 2019 Oct;574(7776):45-56 [PMID: 31578484]
  46. Evid Based Complement Alternat Med. 2022 Jan 15;2022:8528938 [PMID: 35075366]
  47. Neural Regen Res. 2018 Aug;13(8):1390-1395 [PMID: 30106051]
  48. J Evid Based Med. 2012 Feb;5(1):12-24 [PMID: 23528116]
  49. Biomed Res Int. 2015;2015:261620 [PMID: 26161392]
  50. Complement Ther Med. 2014 Dec;22(6):965-9 [PMID: 25453515]
  51. Exp Ther Med. 2018 Jul;16(1):310-320 [PMID: 29896255]
  52. Exp Ther Med. 2013 Sep;6(3):699-702 [PMID: 24137250]
  53. Annu Rev Immunol. 2011;29:235-71 [PMID: 21219185]
  54. Front Aging Neurosci. 2021 Jul 19;13:706834 [PMID: 34349636]
  55. Clin Rev Allergy Immunol. 2020 Jun;58(3):313-325 [PMID: 31256327]
  56. Am J Chin Med. 2007;35(1):35-51 [PMID: 17265549]
  57. J Exp Clin Cancer Res. 2019 Jan 7;38(1):6 [PMID: 30616627]
  58. J Vis Exp. 2016 Jul 16;(113): [PMID: 27501193]
  59. Neurosci Biobehav Rev. 2011 Jan;35(3):680-7 [PMID: 20800613]
  60. Explore (NY). 2008 May-Jun;4(3):170-7 [PMID: 18466847]
  61. J Leukoc Biol. 2019 Jun;105(6):1319-1329 [PMID: 31107565]
  62. Annu Rev Immunol. 2017 Apr 26;35:441-468 [PMID: 28226226]
  63. Int Rev Neurobiol. 2013;111:xv-xviii [PMID: 24215929]
  64. Int Rev Cell Mol Biol. 2019;348:123-178 [PMID: 31810552]
  65. Int J Mol Sci. 2019 Nov 25;20(23): [PMID: 31775332]
  66. Mayo Clin Proc. 2020 Aug;95(8):1671-1683 [PMID: 32499125]
  67. Front Neurosci. 2021 Aug 02;15:695670 [PMID: 34408622]
  68. Front Oncol. 2022 Apr 25;12:864046 [PMID: 35547876]
  69. J Cancer. 2021 Oct 11;12(23):7003-7009 [PMID: 34729102]
  70. Oncol Lett. 2018 Jan;15(1):189-194 [PMID: 29391879]
  71. Chin J Integr Med. 2011 Mar;17(3):166-72 [PMID: 21359916]
  72. Front Surg. 2022 May 12;9:901638 [PMID: 35647012]
  73. Cells. 2020 Jul 17;9(7): [PMID: 32709045]
  74. J Tradit Chin Med. 2014 Oct;34(5):550-4 [PMID: 25417404]
  75. Cells. 2021 May 21;10(6): [PMID: 34063789]
  76. Am J Chin Med. 2007;35(6):955-65 [PMID: 18186582]
  77. Adv Drug Deliv Rev. 2017 May 15;114:206-221 [PMID: 28449873]
  78. Acupunct Med. 2013 Mar;31(1):51-6 [PMID: 23315447]
  79. Life Sci. 2021 May 1;272:119259 [PMID: 33636172]
  80. Mol Cancer. 2020 Aug 6;19(1):120 [PMID: 32762681]
  81. Front Immunol. 2021 Jan 21;11:609705 [PMID: 33552068]
  82. Nat Immunol. 2013 Oct;14(10):1014-22 [PMID: 24048123]
  83. Neural Regen Res. 2021 May;16(5):944-954 [PMID: 33229734]
  84. Trends Cancer. 2020 Jul;6(7):605-618 [PMID: 32610070]
  85. BMC Complement Altern Med. 2013 Dec 17;13:362 [PMID: 24344728]
  86. Immunity. 2021 Oct 12;54(10):2194-2208 [PMID: 34644556]
  87. J Altern Complement Med. 2009 Jul;15(7):745-53 [PMID: 19552597]
  88. Blood. 2019 May 16;133(20):2159-2167 [PMID: 30898857]
  89. Cell. 2019 Oct 3;179(2):292-311 [PMID: 31585077]
  90. Integr Cancer Ther. 2018 Jun;17(2):401-410 [PMID: 28870114]

MeSH Term

Acupuncture Therapy
Immunomodulation
Immunotherapy
Immunosuppression Therapy
Adaptive Immunity

Word Cloud

Created with Highcharts 10.0.0acupuncturetumorimmunemicroenvironmentcellsimmunotherapyTIMEtreatmenttraditionalChinesemedicinemechanismsimmunityconstantlydeeperunderstandingindividualizedprecisiontherapyincreasinglydevelopedpersonalizedmainlyconsistsinfiltratingneuroendocrineextracellularmatrixlymphaticvesselnetworketcinternalenvironmentbasissurvivaldevelopmentcharacteristicshownpotentiallybeneficialimpactscurrentlyavailableinformationdemonstratedregulatestateimmunosuppressionrangepathwayseffectivewayunderstandactionanalyzeresponsefollowingsystemresearchreviewedregulatingimmunologicalstatusbasedinnateadaptiveResearchprogressimmunomodulatorymechanismcancer

Similar Articles

Cited By

No available data.